Physician profile
Paul R Silverman
NPI 1336132182
$13,749.44
in general payments reported to CMS, 2019-2025
25 companies · $1,051 in 2025
The $1,051 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,110 · 2020: $933 · 2021: $879 · 2022: $2,219 · 2023: $744 · 2024: $6,813 · 2025: $1,051.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $5,491 · Food and Beverage: $3,117.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $5,491.48 |
| Food and Beverage | $3,116.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $6,750.31 | 2021-2025 | Symplicity G3, Onyx Frontier, Affera Mapping System |
| Janssen Pharmaceuticals, INC | $1,774.70 | 2019-2024 | Xarelto |
| Abiomed | $1,404.09 | 2019-2025 | Impella |
| Abbott Laboratories | $972.12 | 2020-2022 | |
| Novartis Pharmaceuticals Corporation | $388.65 | 2019-2025 | |
| Biotronik INC. | $370.83 | 2021-2024 | Orsiro Mission |
| Tactile Systems Technology INC | $259.47 | 2023-2025 | Flexitouch Plus, Entre Plus, Nimbl |
| Medtronic Vascular, INC. | $231.49 | 2019-2020 | |
| Endologix LLC | $197.02 | 2025 | Torus Stent Graft System, Endocross Device |
| Amgen INC. | $195.46 | 2019-2025 | Repatha |
| Atricure, INC. | $178.37 | 2025 | Epi-Sense Guided Coagulation System With Visitrax |
| Boston Scientific Corporation | $137.35 | 2021 | |
| Cardiva Medical, INC. | $135.60 | 2024-2025 | Savvywire, Optowire |
| Pfizer INC. | $132.32 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $127.49 | 2019-2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $98.64 | 2019-2023 | Jardiance |
| Esperion Therapeutics, INC. | $86.03 | 2021-2023 | Nexletol |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $84.72 | 2019-2025 | Lifevest |
| E.R. Squibb & Sons, L.L.C. | $73.49 | 2019-2024 | Camzyos |
| Novo Nordisk INC | $62.08 | 2021-2023 | Ozempic, Rybelsus |
| Johnson & Johnson Health Care Systems INC. | $25.28 | 2022 | |
| Terumo Medical Corporation | $19.33 | 2022 | |
| Merck Sharp & Dohme LLC | $16.31 | 2025 | Verquvo |
| Chiesi USA, INC. | $16.22 | 2023 | Kengreal |
| Regeneron Healthcare Solutions, INC. | $12.07 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Silverman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.